352 related articles for article (PubMed ID: 28324063)
1. DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients.
Castagna MG; Dentice M; Cantara S; Ambrosio R; Maino F; Porcelli T; Marzocchi C; Garbi C; Pacini F; Salvatore D
J Clin Endocrinol Metab; 2017 May; 102(5):1623-1630. PubMed ID: 28324063
[TBL] [Abstract][Full Text] [Related]
2. No Effect of the Thr92Ala Polymorphism of Deiodinase-2 on Thyroid Hormone Parameters, Health-Related Quality of Life, and Cognitive Functioning in a Large Population-Based Cohort Study.
Wouters HJ; van Loon HC; van der Klauw MM; Elderson MF; Slagter SN; Kobold AM; Kema IP; Links TP; van Vliet-Ostaptchouk JV; Wolffenbuttel BH
Thyroid; 2017 Feb; 27(2):147-155. PubMed ID: 27786042
[TBL] [Abstract][Full Text] [Related]
3. Type 2 Deiodinase Thr92Ala Polymorphism and Aging Are Associated with a Decreased Pituitary Sensitivity to Thyroid Hormone.
Luongo C; De Stefano MA; Ambrosio R; Volpe F; Porcelli T; Golia V; Bellevicine C; Troncone G; Masone S; Damiano V; Matano E; Klain M; Schlumberger M; Salvatore D
Thyroid; 2023 Mar; 33(3):294-300. PubMed ID: 36680751
[No Abstract] [Full Text] [Related]
4. Variants in MCT10 protein do not affect FT3 levels in athyreotic patients.
Cantara S; Ricci C; Maino F; Marzocchi C; Pacini F; Castagna MG
Endocrine; 2019 Dec; 66(3):551-556. PubMed ID: 31280469
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiological relevance of deiodinase polymorphism.
Bianco AC; Kim BS
Curr Opin Endocrinol Diabetes Obes; 2018 Oct; 25(5):341-346. PubMed ID: 30063552
[TBL] [Abstract][Full Text] [Related]
6. Type 2 deiodinase polymorphism causes ER stress and hypothyroidism in the brain.
Jo S; Fonseca TL; Bocco BMLC; Fernandes GW; McAninch EA; Bolin AP; Da Conceição RR; Werneck-de-Castro JP; Ignacio DL; Egri P; Németh D; Fekete C; Bernardi MM; Leitch VD; Mannan NS; Curry KF; Butterfield NC; Bassett JHD; Williams GR; Gereben B; Ribeiro MO; Bianco AC
J Clin Invest; 2019 Jan; 129(1):230-245. PubMed ID: 30352046
[TBL] [Abstract][Full Text] [Related]
7. Serum Thyroid Hormone Balance in Levothyroxine Monotherapy-Treated Patients with Atrophic Thyroid After Radioiodine Treatment for Graves' Disease.
Ito M; Kawasaki M; Danno H; Kohsaka K; Nakamura T; Hisakado M; Yoshioka W; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Nakamura H; Miyauchi A
Thyroid; 2019 Oct; 29(10):1364-1370. PubMed ID: 31411123
[No Abstract] [Full Text] [Related]
8. Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis.
Heemstra KA; Hoftijzer HC; van der Deure WM; Peeters RP; Fliers E; Appelhof BC; Wiersinga WM; Corssmit EP; Visser TJ; Smit JW
Clin Endocrinol (Oxf); 2009 Aug; 71(2):279-83. PubMed ID: 19018782
[TBL] [Abstract][Full Text] [Related]
9. Identification of Resistance to Exogenous Thyroxine in Humans.
Lacámara N; Lecumberri B; Barquiel B; Escribano A; González-Casado I; Álvarez-Escolá C; Aleixandre-Blanquer F; Morales F; Alfayate R; Bernal-Soriano MC; Miralles R; Yildirim Simsir I; Özgen AG; Bernal J; Berbel P; Moreno JC
Thyroid; 2020 Dec; 30(12):1732-1744. PubMed ID: 32498666
[No Abstract] [Full Text] [Related]
10. The Thr92Ala 5' type 2 deiodinase gene polymorphism is associated with a delayed triiodothyronine secretion in response to the thyrotropin-releasing hormone-stimulation test: a pharmacogenomic study.
Butler PW; Smith SM; Linderman JD; Brychta RJ; Alberobello AT; Dubaz OM; Luzon JA; Skarulis MC; Cochran CS; Wesley RA; Pucino F; Celi FS
Thyroid; 2010 Dec; 20(12):1407-12. PubMed ID: 21054208
[TBL] [Abstract][Full Text] [Related]
11. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy.
Jonklaas J; Davidson B; Bhagat S; Soldin SJ
JAMA; 2008 Feb; 299(7):769-77. PubMed ID: 18285588
[TBL] [Abstract][Full Text] [Related]
12. The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe.
de Jong FJ; Peeters RP; den Heijer T; van der Deure WM; Hofman A; Uitterlinden AG; Visser TJ; Breteler MM
J Clin Endocrinol Metab; 2007 Feb; 92(2):636-40. PubMed ID: 17105838
[TBL] [Abstract][Full Text] [Related]
13. THERAPY OF ENDOCRINE DISEASE: T4 + T3 combination therapy: is there a true effect?
Wiersinga WM
Eur J Endocrinol; 2017 Dec; 177(6):R287-R296. PubMed ID: 28855267
[TBL] [Abstract][Full Text] [Related]
14. Type II deiodinase polymorphisms and serum thyroid hormone levels in patients with mild cognitive impairment.
Luo M; Zhou XH; Zou T; Keyim K; Dong LM
Genet Mol Res; 2015 May; 14(2):5407-16. PubMed ID: 26125736
[TBL] [Abstract][Full Text] [Related]
15. Biochemical Markers Reflecting Thyroid Function in Athyreotic Patients on Levothyroxine Monotherapy.
Ito M; Miyauchi A; Hisakado M; Yoshioka W; Ide A; Kudo T; Nishihara E; Kihara M; Ito Y; Kobayashi K; Miya A; Fukata S; Nishikawa M; Nakamura H; Amino N
Thyroid; 2017 Apr; 27(4):484-490. PubMed ID: 28056660
[TBL] [Abstract][Full Text] [Related]
16. Association of DIO2 and MCT10 Polymorphisms With Persistent Symptoms in LT4-Treated Patients in the UK Biobank.
Jensen CZ; Isaksen JL; Ahlberg G; Olesen MS; Nygaard B; Ellervik C; Kanters JK
J Clin Endocrinol Metab; 2024 Jan; 109(2):e613-e622. PubMed ID: 37740545
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism.
Shakir MKM; Brooks DI; McAninch EA; Fonseca TL; Mai VQ; Bianco AC; Hoang TD
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4400-e4413. PubMed ID: 34185829
[TBL] [Abstract][Full Text] [Related]
18. Association between serum thyroid hormone balance and thyroid volume in patients treated with levothyroxine monotherapy for hypothyroidism.
Takahashi S; Ito M; Masaki Y; Hada M; Minakata M; Kohsaka K; Nakamura T; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Akamizu T; Miyauchi A
Endocr J; 2021 Mar; 68(3):353-360. PubMed ID: 33239477
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3'-triiodothyronine therapy.
Appelhof BC; Peeters RP; Wiersinga WM; Visser TJ; Wekking EM; Huyser J; Schene AH; Tijssen JG; Hoogendijk WJ; Fliers E
J Clin Endocrinol Metab; 2005 Nov; 90(11):6296-9. PubMed ID: 16144953
[TBL] [Abstract][Full Text] [Related]
20. Increased Thyroid-Hormone Requirements Consistent With Type 3 Deiodinase Induction Related to Ibrutinib in a Thyroidectomized Woman.
Mazori AY; Skamagas M
AACE Clin Case Rep; 2021; 7(2):121-123. PubMed ID: 34095468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
